Clinical Trials Logo

Parkinson Disease clinical trials

View clinical trials related to Parkinson Disease.

Filter by:

NCT ID: NCT03562494 Not yet recruiting - Parkinson Disease Clinical Trials

VY-AADC02 for Parkinson's Disease With Motor Fluctuations

Start date: June 2018
Phase: Phase 2
Study type: Interventional

The objectives of this study are to assess the distribution, efficacy, and safety of VY-AADC02 in Patients with Parkinson's Disease with Motor Fluctuations.

NCT ID: NCT03562403 Not yet recruiting - Clinical trials for Parkinson Disease, Essential Tremors and Dystonia

DBS in the Treatment of Intractable Movement Disorders

Start date: July 2018
Phase: N/A
Study type: Interventional

The aim of this study is to observe the efficacy of Deep Brain Stimulation in the treatment of Parkinson's disease,Essential Tremors and Dystonia in our locality.

NCT ID: NCT03560089 Not yet recruiting - Parkinson Disease Clinical Trials

Serious Games Rehabilitation Programme to Treat Gait and Balance Disorders in PD Patients

PARKGAME-II
Start date: July 1, 2018
Phase: N/A
Study type: Interventional

To test the effects of a serious game rehabilitation programme in 50 patients with Parkinson's disease with gait and balance disorders in a randomised controlled study

NCT ID: NCT03558568 Recruiting - Parkinson Clinical Trials

The Effect of Deep Brain Stimulation on Facial Expressions.

STN-DBS
Start date: May 1, 2018
Phase: N/A
Study type: Interventional

Whether Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS), a treatment commonly used to ameliorate the motor symptoms of Parkinson's disease (PD), affects on facial expressions is unclear. The purpose of this study was to investigate the potential effects of DBS and different frequencies on facial expressions of PD patients by volunteers via a web site: http://www.supporttoscience.com

NCT ID: NCT03555695 Recruiting - Parkinson Disease Clinical Trials

Kick Out Parkinson's Disease

Start date: June 30, 2018
Phase: N/A
Study type: Interventional

The benefits of exercise for general health and wellbeing in older adults are well-established. Balance exercises such as tai chi and yoga, along with resistance training, can improve or maintain physical function in older adults and enhance muscle strength. Furthermore, aerobic activity is critical for maintaining and improving cardiovascular and functional health. Noncontact boxing has recently seen a surge in popularity among individuals with Parkinson's Disease (PD), with components of both aerobic and balance exercise. While participants anecdotally note improvements in stress and physical function, this has only been minimally studied. However, drawing on this experience and the combined aerobic, balance, and mindfulness practices that comprise karate, we hypothesize that participation in structured karate programs may offer similar or greater benefits. Specifically, the aim of this study is to test whether and to what degree a community-based karate class tailored for individuals with early- to middle-stage Parkinson's Disease (PD) 1) is feasible; and 2) improves objective and patient-reported outcomes.

NCT ID: NCT03555292 Recruiting - Parkinson Disease Clinical Trials

11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

Start date: July 12, 2017
Phase: Phase 2
Study type: Interventional

To evaluate the potential contribution of amyloid burden, as indexed by 11C-Pittsburgh compound B (PiB) retention, to the progression of cognitive impairments in patients with Parkinson's disease(PD).

NCT ID: NCT03554551 Not yet recruiting - Parkinson Disease Clinical Trials

Imaging the Vesicular Acetylcholine Transporter Using 18F-FEOBV PET in Parkinsons Disease

Start date: June 15, 2018
Phase:
Study type: Observational

Patients with Parkinson's disease (PD) often display symptoms, such as constipation, due to denervation of the cholinergic nerves in the gut. It has been hypothesized that PD initiates in the gut years prior to diagnosis. To gain a detailed understanding of the early stages of PD, techniques for quantification of cholinergic nerves are needed. The PET tracer 18F-FEOBV binds specifically to the vesicular acetylcholine transporter, situated in presynaptic cholinergic nerve terminals. The investigators will investigate 18F-FEOBV uptake in the brain and internal organs of 15 patients with moderate-stage PD and compare to 15 healthy controls. Furthermore, findings are correlated to validated clinical tests of the autonomic nervous system. The aim is to validate 18F-FEOBV PET/CT as a clinical imaging modality to diagnose parasympathetic denervation in PD.

NCT ID: NCT03552861 Not yet recruiting - Clinical trials for TMS Protocols in the Treatment of PD

Standardization and Optimization of TMS Protocols for the Treatment of PD With Depression or Cognitive Impairment

Start date: June 2018
Phase: N/A
Study type: Interventional

The goal of this study is to determine whether transcranial magnetic stimulation (TMS) is an effective treatment in Parkinson's disease patients with depression or cognitive impairment. The study consists of seven total visits to all. Compensation will be provided for each visit.

NCT ID: NCT03552484 Recruiting - Clinical trials for Multiple System Atrophy

In-Home Care for Patients With PSP and Related Disorders

Start date: June 30, 2018
Phase: N/A
Study type: Interventional

Progressive Supranuclear Palsy and related disorders (PRD) are debilitating, costly, and understudied conditions. Improving access to comprehensive, specialized, in-home patient care offers the potential to minimize the downward spiral of morbidity and preventable healthcare utilization. The aim of this study is to test whether and to what degree an interdisciplinary home visit program will improve patient- and caregiver-reported outcomes, and to identify unmet needs in this population.

NCT ID: NCT03552068 Not yet recruiting - Parkinson's Disease Clinical Trials

Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:

ID-CLO
Start date: September 1, 2018
Phase: Phase 2
Study type: Interventional

Noradrenergic system is involved in impulsivity in the general population and is altered in Parkinson's disease (PD) in the early stages of the disease. Thus, targeting this system could be of interest in impulse control disorder (ICD). Acting on the noradrenergic system is possible using clonidine, an α2 adrenergic agonist largely used in hypertension treatment and that induces a decrease of NADR release. Thus, our aim is to conduct a proof of concept study evaluating the efficacy and safety of clonidine on ICD in PD. This study is a multicenter, randomized, double-blind, placebo-controlled in parallel group clinical trial.